CAR T-Cell Therapy Shows “Impressive” Results in Multiple Myeloma

Wayne Kuznar

Immunotherapy, Web Exclusives

Atlanta, GA—Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T-cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.

In the phase 1, dose-escalation clinical trial CRB-401 of 21 patients with multiple myeloma that relapsed after a median of 7 lines of therapy, the response to a single infusion of the CAR T-cell therapy called bb2121, which was engineered to target BCMA, was 86%. The response rate increased to 94% in 18 patients who had received higher active doses of the infused CAR T-cells, reported James N. Kochenderfer, MD, Investigator, Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.

The dose-escalation clinical trial of bb2121 was conducted in patients with relapsed or refractory multiple myeloma who received at least 3 previous lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or who were double-refractory, and who had at least 50% BCMA expression on plasma cells.

Study Details

The study enrolled 24 patients, 21 of whom had received bb2121. The study’s objective was to identify the maximum tolerated dose. Overall, 29% of patients had disease that was refractory to 5 common multiple myeloma therapies, including bortezomib (Velcade), lenalidomide (Revlimid), carfilzomib (Kyprolis), pomalidomide (Pomalyst), and daratumumab (Darzalex).

After lymphodepletion with fludarabine and cyclophosphamide, patients received from 50 × 106 to 800 × 106 CAR T-cells. The median follow-up was 35 weeks, with the first response assessment at week 4.

Overall, 43% of the study cohort had high-risk cytogenetics. All patients had received previous autologous stem-cell transplantation.

“Generally, this was a very well-tolerated CAR T-cell product,” said Dr Kochenderfer. A total of 71% of patients had cytokine release syndrome (CRS), with 10% being grade ≥3. The 2 reported grade 3 CRS events resolved within 24 hours. Overall, 24% of patients had neurologic toxicity, but no grade ≥3 neurotoxicity, or dose-limiting toxicities were observed. Overall, 5 deaths occurred during the study, 3 because of disease progression at the 50 × 106 dose, which was deemed not to have clinical activity. Overall, 14 patients had ≥1 serious adverse events.

Prolonged Duration of Response

Among the 18 patients who received active doses of bb2121 (150 × 106 to 800 × 106 CAR T-cells), 17 (94%) had an objective response, with a complete response rate that improved from 27% in May 2017, to 56% at data lock in October 2017. After 40 weeks of follow-up, 9 of 10 evaluable patients had no minimal residual disease. Some responses have been ongoing for more than 1 year.

“Our longest response has been going on 68 weeks at this point. In general, very impressive responses when compared to my previous experience treating multiple myeloma,” said Dr Kochenderfer. Responses continued to improve as late as month 15, and the duration of response has not yet been reached. Overall, 2 patients who received active doses of bb2121 were in complete remission at the time of their deaths.

The median time to first response was 1.02 months, the median time to best response was 3.74 months, and the median time to complete response was 3.84 months. The median progression-free survival has not been reached in the active-dose cohorts. At 9 months, progression-free survival was 71%.

Emerging Therapies, Web Exclusives - November 5, 2018

TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition

According to data from a preliminary phase 1b clinical trial, a novel approach using the investigational toll-like receptor 9 (TLR-9) agonist CMP-001 in combination with pembrolizumab may have the potential to reverse resistance to anti–PD-1 therapy.

Cancer Screening and COVID-19, Web Exclusives - October 5, 2020

Impact of COVID-19 on Cancer Screening and How We Can Get Back on Track

For decades, healthcare professionals have worked diligently to teach individuals that screening is a valuable tool for preventing and detecting cancer. This has not been an easy mission, and nurses and physicians have had to debunk the myths, bias, and misinformation that deter patients from getting screened annually or according to specific guidelines set forth by organizations such as the Centers for Disease Control and Prevention (CDC) and the American Cancer Society (ACS). Although clinicians have been telling their patients—and the population at large—not to put off cancer screening because it saves lives, when the COVID-19 pandemic hit in March of this year, the dialogue changed.